| Title |
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
| Description |
The study will submit its CSR data to Health Authority of Japan,include pk and img data. |
| Organism |
Homo sapiens |
| Data Type |
Other Type of Clinical information |
| Data Accessibility |
Controlled-access |
| BioProject |
PRJCA013230 |
| Release Date |
2022-12-31 |
| Submitter |
Xiaoxiao Wang (mandy.wang@bms.com) |
| Organization |
Bristol-Myers Squibb (China) Investment Co., Ltd. |
| Submission Date |
2022-11-29 |